keyword
MENU ▼
Read by QxMD icon Read
search

macroprolactinoma

keyword
https://www.readbyqxmd.com/read/28670538/menstrual-cycle-abnormalities-in-patients-with-prolactinoma-and-drug-induced-hyperprolactinemia
#1
Bindu Kulshreshtha, Isha Pahuja, Deepak Kothari, Indu Chawla, Neera Sharma, Shikha Gupta, Anuja Mittal
BACKGROUND AND OBJECTIVE: Hyperprolactinemia affects the reproductive endocrine axis; however, the degree of dysfunction may vary depending on etiology. The aim of the present study was to analyze menstrual cyclicity in patients with prolactinoma and drug-induced hyperprolactinemia (DIH). METHODOLOGY: Patients with prolactinoma and DIH were retrospectively analyzed for menstrual cyclicity at presentation and response to therapy. RESULTS: Of 128 females with hyperprolactinemia, 58 had prolactinoma (41 microadenoma and 17 macroadenoma) and 39 had DIH...
July 2017: Indian Journal of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28626987/prolactinomas-diagnosed-in-the-postmenopausal-period-clinical-phenotype-and-outcomes
#2
Sandhya Santharam, Metaxia Tampourlou, Wiebke Arlt, John Ayuk, Neil Gittoes, Andrew Toogood, Rachel Webster, Niki Karavitaki
OBJECTIVE: Most prolactinomas in females are diagnosed during the reproductive age and the majority are microadenomas. Prolactinomas detected in the postmenopausal period are less common with limited published data on their presentation and prognosis. Our objective was to assess the presenting clinical, biochemical and imaging findings, as well as the outcomes of women diagnosed with a prolactinoma in the postmenopausal period. DESIGN AND METHODS: We undertook a retrospective cohort study of women diagnosed with prolactinoma after menopause and followed-up in a large UK pituitary center...
June 19, 2017: Clinical Endocrinology
https://www.readbyqxmd.com/read/28608351/course-of-aggressive-somatotroph-corticotroph-and-mammotroph-tumors-under-temozolomide-report-of-three-cases-and-review-of-the-literature
#3
Berna İmge Aydoğan, Uğur Ünlütürk, Rıfat Emral, Sevim Güllü
Treatment of aggressive pituitary tumors may be challenging. Temozolomide (TMZ) is a promising agent when conventional treatment methods fail. We present three patients with aggressive pituitary tumors with atypical morphology, who were resistant to conventional treatments and treated with TMZ. First case had a somatotroph adenoma, second a corticotroph adenoma, and the third a macroprolactinoma. We also reviewed the literature reporting TMZ efficacy in somatotroph, corticotroph and mammotroph tumors of pituitary...
May 7, 2017: Turkish Neurosurgery
https://www.readbyqxmd.com/read/28523537/prolactinoma-management-predictors-of-remission-and-recurrence-after-dopamine-agonists-withdrawal
#4
Margarida Teixeira, Pedro Souteiro, Davide Carvalho
OBJECTIVE: Prolactinomas are the most common functional pituitary tumour. Dopamine agonists (DA) are its principal treatment. The criteria that should guide therapy withdrawal and the factors that influence disease remission or relapse are not yet fully established. Our purpose is to evaluate the proportion of patients who attempted DA withdrawal, and to identify the factors that influence clinicians to try it. In addition, we aim to study the factors that are involved in prolactinoma remission/relapse after therapy withdrawal...
August 2017: Pituitary
https://www.readbyqxmd.com/read/28511976/fertility-pregnancy-and-prolactinoma-a-survey-of-pituitary-surgeons-view-and-review-of-the-literature
#5
Walter C Jean, Daniel R Felbaum
OBJECTIVE: Pituitary surgeons frequently encounter female prolactinoma patients seeking treatment to restore fertility. Current medical guidelines recommend using dopamine agonist (DA) for this, but for fetal safety, DA should stop upon pregnancy confirmation. The probability that prolactinoma may grow during pregnancy makes this last recommendation imperfect. With the advances in endoscopic surgery, we queried the potential role for surgery in these infertile patients, who may be ambivalent about both stopping and continuing DA while pregnant...
August 2017: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/28469923/macroprolactinoma-appearing-after-resolution-of-hydrocephalus
#6
Oscar D Bruno, Ricardo Fernández Pisani, Gabriel Isaac, Armando Basso
SUMMARY: The role of mechanical forces influencing the growth of a pituitary adenoma is poorly understood. In this paper we report the case of a young man with hyperprolactinaemia and an empty sella secondary to hydrocephalia, who developed a macroprolactinoma following the relief of high intraventricular pressure. LEARNING POINTS: The volume of a pituitary tumour may be influenced not only by molecular but also by local mechanical factors.Intratumoural pressure, resistance of the sellar diaphragm and intracranial liquid pressure may play a role in the final size of a pituitary adenoma...
2017: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/28217516/long-term-cardiac-valvulopathy-safety-of-cabergoline-in-prolactinoma
#7
Shruti Khare, Anurag R Lila, Rishikesh Patil, Milind Phadke, Prafulla Kerkar, Tushar Bandgar, Nalini S Shah
BACKGROUND: Clinical relevance of association of cabergoline use for hyperprolactinemia and cardiac valvulopathy remains unclear. OBJECTIVE: The aim of the study was to determine the prevalence of valvular heart abnormalities in patients taking cabergoline for the treatment of prolactinoma and to explore any associations with the cumulative dose of drug used. DESIGN: A cross-sectional echocardiographic study was performed in patients who were receiving cabergoline therapy for prolactinoma...
January 2017: Indian Journal of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28209309/cluster-headache-and-macroprolactinoma-case-report-of-a-rare-but-potential-important-causality
#8
Lukas Andereggen, Marie-Luise Mono, Frauke Kellner-Weldon, Emanuel Christ
While headache is not an uncommon symptom in patients suffering from pituitary adenomas, cluster headache (CH) has rarely been reported in such cases. Headache associated with hyperprolactinemia has been reported to be responsive to dopamine agonists (DA agonists) in many patients. We report on a patient with refractory CH secondary to a macroprolactinoma who showed immediate and permanent clinical and radiologic recovery following medical treatment with DA agonists. Measurement of prolactin levels in addition to cranial magnetic resonance imaging might be considered in patients with refractory CH, until the significance of this potential causality becomes clearer...
June 2017: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/28096982/the-birth-and-rise-of-a-craniopharyngioma-the-radiological-evolution-of-an-incidental-craniopharyngioma-detected-on-serial-mri-during-medical-treatment-of-a-macroprolactinoma
#9
Stefano Mariotti, Marco Losa, Pietro Mortini, Luca Saba
This case demonstrates the rare coexistence of a prolactinoma with craniopharyngioma and documents its radiological growth. This case suggests that patients with pituitary neoplasms should be followed closely and although prolactinomas can often be managed medically, a coexistent other lesion may require surgery for histological assessment and to reduce mass effect.
January 2017: Clinical Case Reports
https://www.readbyqxmd.com/read/28073906/mri-follow-up-is-unnecessary-in-patients-with-macroprolactinomas-and-long-term-normal-prolactin-levels-on-dopamine-agonist-treatment
#10
MULTICENTER STUDY
J Eroukhmanoff, I Tejedor, I Potorac, T Cuny, J F Bonneville, H Dufour, G Weryha, A Beckers, P Touraine, T Brue, F Castinetti
OBJECTIVE: Both antitumor and antisecretory efficacies of dopamine agonists (DA) make them the first-line treatment of macroprolactinomas. However, there is no guideline for MRI follow-up once prolactin is controlled. The aim of our study was to determine whether a regular MRI follow-up was necessary in patients with long-term normal prolactin levels under DA. PATIENTS AND METHODS: We conducted a retrospective multicenter study (Marseille, Paris La Pitie Salpetriere and Nancy, France; Liege, Belgium) including patients with macroprolactinomas (largest diameter: >10 mm and baseline prolactin level: >100 ng/mL) treated by dopamine agonists, and regularly followed (pituitary MRI and prolactin levels) during at least 48 months once normal prolactin level was obtained...
March 2017: European Journal of Endocrinology
https://www.readbyqxmd.com/read/27926659/macroprolactinomas-and-nonfunctioning-pituitary-adenomas-and-pregnancy-outcomes
#11
Kimberley Lambert, Kate Rees, Paul T Seed, Mandish K Dhanjal, Marian Knight, David R McCance, Catherine Williamson
OBJECTIVE: To examine the monitoring, management, and outcomes of pituitary tumors in pregnancy. METHODS: A national, prospective, observational, population-based case series study was conducted in all U.K. consultant-led obstetric units over 3 years using the U.K. Obstetric Surveillance System. To evaluate rates of adverse pregnancy outcomes, women with a macroprolactinoma (10 mm or greater) or nonfunctioning pituitary adenoma, diagnosed before or during pregnancy, were compared with two comparison groups: 1) a U...
January 2017: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/27908214/pregnancy-and-tumor-outcomes-in-infertile-women-with-macroprolactinoma-on-cabergoline-therapy
#12
Ashu Rastogi, Sanjay K Bhadada, Anil Bhansali
Hyperprolactinemia and prolactinomas cause infertility in significant number of women. But, pregnancy may lead to post-partum remission of hyperprolactinemia. The data on pregnancy and tumor outcome in women with macroprolactinoma conceiving on Cabergoline (CAB) therapy is increasing but still less than with Bromocriptine. We studied the incidence of fetal malformations, hyperprolactinemia and tumor course after gestation in infertile women harboring macroprolactinoma, who conceived on CAB therapy during the year 2005-2015...
December 2, 2016: Gynecological Endocrinology
https://www.readbyqxmd.com/read/27855233/a-macroprolactinoma-becoming-resistant-to-cabergoline-and-developing-atypical-pathology
#13
Emilia Sbardella, George Farah, Ahmed Fathelrahman, Simon Cudlip, Olaf Ansorge, Niki Karavitaki, Ashley B Grossman
Pituitary adenomas are a common intracranial neoplasm, usually demonstrating a benign phenotype. They can be classified according to pathological, radiological or clinical behaviour as typical, atypical or carcinomas, invasive or noninvasive, and aggressive or nonaggressive. Prolactinomas account for 40-60% of all pituitary adenomas, with dopamine agonists representing the first-line treatment and surgery/radiotherapy reserved for drug intolerance/resistance or in neuro-ophthalmological emergencies. We present the case of a 62-year-old man with an apparently indolent prolactin-secreting macroadenoma managed with partial resection and initially showing a biochemical response to cabergoline...
2016: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/27783196/management-of-prolactinomas-a-survey-of-physicians-from-the-middle-east-and-north-africa
#14
Salem A Beshyah, Ibrahim H Sherif, Farida Chentli, Amir Hamrahian, Aly B Khalil, Hussein Raef, Mohamed El-Fikki, Selim Jambart
BACKGROUND: Prolactinomas are the commonest functional tumors of the pituitary gland. There are still controversies regarding medical therapy in specific clinical situations. Patients may be managed by different specialists in the Middle East and North Africa (MENA) region and no data exist on patterns of clinical management. OBJECTIVES: To ascertain the diagnostic and therapeutic approaches to prolactinomas among relevant professionals from the MENA region. METHODS: An online survey of a large sample of physicians was conducted...
April 2017: Pituitary
https://www.readbyqxmd.com/read/27682355/surgical-outcomes-of-prolactinomas-in-recent-era-results-of-a-heterogenous-group
#15
Diane Donegan, John L D Atkinson, Mark Jentoft, Neena Natt, Tod B Nippoldt, Bradley Erickson, Fredric Meyer, Dana Erickson
OBJECTIVE: Prolactinomas are primarily treated with medical therapy. Given the efficacy of dopamine agonists (DAs), surgery has remained a second-line treatment option. Despite medical therapy, some tumors display resistance and/or patients maybe intolerant of DA and require alternative treatment options. We examined the indications, efficacy, and safety of pituitary surgery for the treatment of prolactinomas. METHODS: We performed a retrospective analysis of all patients who had surgery for a prolactinoma at our institution from January 1993 to October 2014...
January 2017: Endocrine Practice
https://www.readbyqxmd.com/read/27668187/approach-to-the-management-of-rare-clinical-presentations-of-macroprolactinomas-in-reproductive-aged-women
#16
Ana Espinosa De Ycaza, Alice Y Chang, Jani R Jensen, Zaraq Khan, Dana Erickson
OBJECTIVE: To describe 2 cases of macroprolactinomas with atypical presentation in women desiring pregnancy that illustrate important considerations in the management approach for macroprolactinomas in reproductive-aged women. PATIENTS: Case 1 was a 26-year-old woman referred to our institution for possible tumor resection after pituitary apoplexy during her first pregnancy. Instead, she underwent treatment with cabergoline for a year with goals of normalization of prolactin and decrease in tumor size to <1 cm before trying to conceive...
October 2015: Case Reports in Women's Health
https://www.readbyqxmd.com/read/27651307/long-term-results-of-cabergoline-therapy-for-macroprolactinomas-and-analyses-of-factors-associated-with-remission-after-withdrawal
#17
Shinya Watanabe, Hiroyoshi Akutsu, Shingo Takano, Tetsuya Yamamoto, Eiichi Ishikawa, Hiroaki Suzuki, Akira Matsumura
OBJECTIVE: Withdrawal of cabergoline is generally challenging, especially in patients with large or invasive macroprolactinomas. Therefore, we aimed to assess long-term results of cabergoline therapy for macroprolactinomas and remission achievement results after withdrawal in patients with macroprolactinomas. We also investigated clinical characteristics and factors related to remission after withdrawal. METHODS: This was an institutional review board-approved retrospective analysis...
February 2017: Clinical Endocrinology
https://www.readbyqxmd.com/read/27641080/long-term-outcome-of-macroprolactinomas
#18
MULTICENTER STUDY
Lori Képénékian, Hélène Cebula, Frédéric Castinetti, Thomas Graillon, Thierry Brue, Bernard Goichot
OBJECTIVE: Management of macroprolactinomas has dramatically changed in recent decades, from surgical to medical treatment as first-line therapy, with the development of dopamine agonists (DA). But few data exist on the long-term outcome of these patients. PATIENTS AND METHODS: Retrospective descriptive multicenter study of patients with macroprolactinoma followed for at least 5 years between 1973 and 2008 at the University Hospitals of Strasbourg and Marseille...
December 2016: Annales D'endocrinologie
https://www.readbyqxmd.com/read/27525431/treatment-of-hyperprolactinaemia-reduces-total-cholesterol-and-ldl-in-patients-with-prolactinomas
#19
Verena Schwetz, Rosaria Librizzi, Christian Trummer, Georg Theiler, Claudia Stiegler, Thomas R Pieber, Barbara Obermayer-Pietsch, Stefan Pilz
Previous studies suggest that hyperprolactinaemia might have adverse effects on lipid and glucose metabolism. We therefore aimed to evaluate whether dopamine agonist treatment with cabergoline has significant effects on blood lipids, fasting glucose and HbA1c levels in patients with micro- or macroprolactinoma. In this retrospective observational study the main outcome measures are changes in parameters of glucose and lipid metabolism compared at hyperprolactinaemia and after achievement of normoprolactinaemia by cabergoline treatment...
August 15, 2016: Metabolic Brain Disease
https://www.readbyqxmd.com/read/27487374/prolactinomas-may-have-unusual-presentations-resulting-from-massive-extrasellar-tumor-extension
#20
Marise Ribeiro de Sousa Berriel, Giovanna Aparecida Balarini Lima, Alessandro Severo Alves de Melo, Maria Laura Vasconcelos Dos Santos, Hassan Rahhal, Giselle Fernandes Taboada
The purpose of this case series is to report eight patients with giant prolactinomas emphasizing presentations and a treatment complication. The study group included six men and two women. The median age was 29 years (18-54 years); median serum prolactin level was 4,562 ng/ml (1,543-18,690 ng/ml); three patients (37.5%) had panhypopituitarism; median tumor diameter was 50 mm (41-60 mm). Five patients (62.5%) had visual field defects and three had improvement during treatment; six patients (75%) reached prolactin normalization, with a median time of 10...
July 2016: Arquivos de Neuro-psiquiatria
keyword
keyword
59456
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"